Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Brain Bank

Eli Lilly HQ

Lilly taps AstraZeneca for another anti-amyloid drug

MEDI1814 could potentially slow the progression of Alzheimer's

Eli Lilly HQ

Lilly sinks as solanezumab fails again in Alzheimer’s

Amyloid-targeting drug showed no significant evidence of slow in cognitive decline

Eli Lilly HQ

Lilly promises solanezumab news in Alzheimer’s ‘before year-end’

If anti-amyloid drug proves effective, sales could reach $7.5bn according to analysts

- PMLiVE

At current progress, 2025 Alzheimer’s target ‘unlikely to be reached’

Drug development and diagnosis process requires shake-up to create effective therapies

- PMLiVE

Lundbeck trial failure dashes hopes in Alzheimer’s once again

Phase III trial fails to substantially improve cognition despite promising phase II data

- PMLiVE

Alzheimer’s disease: reviewing the immediate treatment horizon

Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.

Blue Latitude Health

Biogen Idec building

Eisai and Biogen plan phase III trials for Alzheimer’s drug

BACE inhibitor E2609 may offer new treatment option

- PMLiVE

Tau protein drug fails late-stage trial

Alzheimer’s disease therapy only showed benefit in patients with no existing treatments

- PMLiVE

Brain training ‘could cut dementia risk’, says study

Findings suggest computerised speed of processing training can reduce cognitive decline by 48 percent

- PMLiVE

Alzheimer’s: the numbers we cannot forget

In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as looking at the some of the...

Blue Latitude Health

AstraZeneca AZ

AZ gets $100m from Lilly as Alzheimer’s drug progresses

BACE inhibitor candidate displays ‘encouraging’ positive safety data

- PMLiVE

Researchers say ‘neurostatins’ may ward off Alzheimer’s

Preclinical studies show bexarotene prevents nerve cell degeneration

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links